<DOC>
	<DOCNO>NCT01233622</DOCNO>
	<brief_summary>This study evaluate efficacy safety vildagliptin 50 mg bid add-on therapy metformin plus glimepiride patient Type 2 Diabetes ( T2D ) .</brief_summary>
	<brief_title>Safety Efficacy Galvus add-on Therapy Metformin Plus Glimepiride</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion Confirmed diagnosis T2DM standard criterion . Treatment oral antidiabetic therapy , stable dose least 12 week prior screen visit . Acceptable background antidiabetic therapy include : metformin ( ≥ 1500 mg ) monotherapy combination SU , TZDs , glinides Age : ≥18 ≤ 80 year HbA1c ≥ 7.5 ≤ 11.0 % Body Mass Index ( BMI ) ≥22 ≤45 kg/m2 Exclusion criterion : FPG ≥ 270 mg/dL ( ≥ 15.0 mmol/L ) Acute metabolic diabetes complication ketoacidosis hyperosmolar state ( coma ) within past 6 month Any follow within past 6 month : Myocardial infarction , TIA stroke , coronary artery bypass surgery percutaneous coronary intervention History hypersensitivity study drug drug similar chemical class Acute infection may affect blood glucose control within 4 week prior screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>